The brief

Analyst view

• Rubedo's senolytic platform targets senescent cells—aging cells that stop dividing and drive inflammation.
• RLS-1496, the world's first GPX4 modulator in human trials, is advancing through Phase 1b/2a in skin conditions and hair loss.
• Phase 1 data in psoriasis and dermatitis showed dose-dependent improvements with no serious adverse events.

Technical approach

As reported

Senolytic approach

Targeting aging cells

Senescent cells accumulate with age, secreting factors that damage tissues. Senolytics eliminate them, clearing the damage.

GPX4 modulation

Triggering selective cell death

GPX4 prevents ferroptosis (iron-driven cell death). Modulating GPX4 triggers ferroptosis in senescent cells while protecting healthy cells.

Topical delivery

Local action on skin

RLS-1496 is topical, allowing high local concentrations while minimizing systemic side effects.